atenolol has been researched along with Alzheimer Disease in 16 studies
Atenolol: A cardioselective beta-1 adrenergic blocker possessing properties and potency similar to PROPRANOLOL, but without a negative inotropic effect.
atenolol : An ethanolamine compound having a (4-carbamoylmethylphenoxy)methyl group at the 1-position and an N-isopropyl substituent.
Alzheimer Disease: A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Alzheimer's disease is the most common cause of dementia." | 1.42 | In Vitro Inhibitory Effects of 8-O-Demethylmaritidine and Undulatine on Acetylcholinesterase and Their Predicted Penetration across the Blood-Brain Barrier. ( Cahlíková, L; Chlebek, J; Hošt'álková, A; Opletal, L; Pérez, DI; Šafratová, M; Štěpánková, Š, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (12.50) | 29.6817 |
| 2010's | 11 (68.75) | 24.3611 |
| 2020's | 3 (18.75) | 2.80 |
| Authors | Studies |
|---|---|
| Marco-Contelles, J | 1 |
| León, R | 1 |
| de los Ríos, C | 1 |
| Samadi, A | 1 |
| Bartolini, M | 2 |
| Andrisano, V | 3 |
| Huertas, O | 1 |
| Barril, X | 1 |
| Luque, FJ | 1 |
| Rodríguez-Franco, MI | 1 |
| López, B | 1 |
| López, MG | 1 |
| García, AG | 1 |
| Carreiras, Mdo C | 1 |
| Villarroya, M | 1 |
| Chiriano, G | 1 |
| De Simone, A | 2 |
| Mancini, F | 1 |
| Perez, DI | 2 |
| Cavalli, A | 1 |
| Bolognesi, ML | 1 |
| Legname, G | 1 |
| Martinez, A | 1 |
| Carloni, P | 1 |
| Roberti, M | 1 |
| Sun, Y | 2 |
| Chen, J | 1 |
| Chen, X | 1 |
| Huang, L | 3 |
| Li, X | 3 |
| Miao, H | 1 |
| Meng, F | 1 |
| Cahlíková, L | 1 |
| Štěpánková, Š | 1 |
| Chlebek, J | 1 |
| Šafratová, M | 1 |
| Hošt'álková, A | 1 |
| Opletal, L | 1 |
| Hroch, L | 1 |
| Benek, O | 1 |
| Guest, P | 1 |
| Aitken, L | 1 |
| Soukup, O | 3 |
| Janockova, J | 1 |
| Musil, K | 1 |
| Dohnal, V | 1 |
| Dolezal, R | 2 |
| Kuca, K | 2 |
| Smith, TK | 1 |
| Gunn-Moore, F | 1 |
| Musilek, K | 1 |
| Xia, CL | 1 |
| Wang, N | 1 |
| Guo, QL | 1 |
| Liu, ZQ | 1 |
| Wu, JQ | 1 |
| Huang, SL | 1 |
| Ou, TM | 1 |
| Tan, JH | 1 |
| Wang, HG | 1 |
| Li, D | 1 |
| Huang, ZS | 1 |
| Baschieri, A | 1 |
| Apperley, KYP | 1 |
| Chen, HH | 1 |
| Guardigni, M | 1 |
| Montanari, S | 1 |
| Kobrlova, T | 1 |
| Valgimigli, L | 1 |
| Keillor, JW | 1 |
| Basso, M | 1 |
| Milelli, A | 1 |
| Kumar, D | 1 |
| Gupta, SK | 1 |
| Ganeshpurkar, A | 1 |
| Gutti, G | 1 |
| Krishnamurthy, S | 1 |
| Modi, G | 1 |
| Singh, SK | 1 |
| Hepnarova, V | 1 |
| Korabecny, J | 1 |
| Matouskova, L | 1 |
| Jost, P | 1 |
| Muckova, L | 1 |
| Hrabinova, M | 1 |
| Vykoukalova, N | 1 |
| Kerhartova, M | 1 |
| Kucera, T | 1 |
| Nepovimova, E | 1 |
| Spilovska, K | 1 |
| Mezeiova, E | 1 |
| Pham, NL | 1 |
| Jun, D | 1 |
| Staud, F | 1 |
| Kaping, D | 1 |
| Hu, J | 1 |
| Pan, T | 1 |
| An, B | 1 |
| Li, Z | 1 |
| Srivastava, P | 1 |
| Tripathi, PN | 1 |
| Sharma, P | 1 |
| Shrivastava, SK | 1 |
| Xie, SS | 2 |
| Liu, J | 2 |
| Tang, C | 1 |
| Pang, C | 1 |
| Li, Q | 1 |
| Qin, Y | 1 |
| Nong, X | 1 |
| Zhang, Z | 2 |
| Guo, J | 2 |
| Cheng, M | 2 |
| Tang, W | 1 |
| Liang, N | 1 |
| Jiang, N | 1 |
| Zhou, W | 1 |
| Wan, Y | 1 |
| Wang, R | 1 |
| Fang, Y | 1 |
| Jin, Y | 1 |
| Liu, W | 2 |
| Liu, X | 1 |
| Tian, L | 1 |
| Gao, Y | 1 |
| Chen, H | 1 |
| Jiang, X | 1 |
| Xu, Z | 1 |
| Ding, H | 1 |
| Zhao, Q | 1 |
16 other studies available for atenolol and Alzheimer Disease
| Article | Year |
|---|---|
Tacripyrines, the first tacrine-dihydropyridine hybrids, as multitarget-directed ligands for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Blood-Brain Barrier; Butyrylcholines | 2009 |
A small chemical library of 2-aminoimidazole derivatives as BACE-1 inhibitors: Structure-based design, synthesis, and biological evaluation.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Animals; Cell Surviv | 2012 |
Inhibition of cholinesterase and monoamine oxidase-B activity by Tacrine-Homoisoflavonoid hybrids.
Topics: Alzheimer Disease; Animals; Blood-Brain Barrier; Cholinesterase Inhibitors; Cholinesterases; Electro | 2013 |
Discovery of indanone derivatives as multi-target-directed ligands against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Blood-Brain Barrier; B | 2014 |
In Vitro Inhibitory Effects of 8-O-Demethylmaritidine and Undulatine on Acetylcholinesterase and Their Predicted Penetration across the Blood-Brain Barrier.
Topics: Acetylcholinesterase; Alzheimer Disease; Amaryllidaceae Alkaloids; Biological Transport; Blood-Brain | 2015 |
Design, synthesis and in vitro evaluation of benzothiazole-based ureas as potential ABAD/17β-HSD10 modulators for Alzheimer's disease treatment.
Topics: 3-Hydroxyacyl CoA Dehydrogenases; Alzheimer Disease; Animals; Benzothiazoles; Cell Survival; CHO Cel | 2016 |
Design, synthesis and evaluation of 2-arylethenyl-N-methylquinolinium derivatives as effective multifunctional agents for Alzheimer's disease treatment.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Blood-Brain Barrier; Cell Death; Cell Line; | 2017 |
Hydroxy-substituted trans-cinnamoyl derivatives as multifunctional tools in the context of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Cinnamates; Dose-Response Relationship, Drug; Free Radical Scavengers; G | 2017 |
Development of Piperazinediones as dual inhibitor for treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Butyrylcholinesterase; Diketopiperazines; Dose-Response Rel | 2018 |
The concept of hybrid molecules of tacrine and benzyl quinolone carboxylic acid (BQCA) as multifunctional agents for Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Butyrylcholinesterase; Cell Line; Cholinesterase I | 2018 |
Synthesis and evaluation of clioquinol-rolipram/roflumilast hybrids as multitarget-directed ligands for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Aminopyridines; Animals; Benzamides; Clioquinol; Cyclic Nucleotide Phosphodiester | 2019 |
Design, synthesis, and evaluation of novel N-(4-phenoxybenzyl)aniline derivatives targeting acetylcholinesterase, β-amyloid aggregation and oxidative stress to treat Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Drug Design; Humans; Oxidative Stres | 2019 |
Design, synthesis and biological evaluation of rasagiline-clorgyline hybrids as novel dual inhibitors of monoamine oxidase-B and amyloid-β aggregation against Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cell Line, Tumor; Cell Survival; Clorgyline; Dose | 2020 |
Design, synthesis, and biological evaluation of novel xanthone-alkylbenzylamine hybrids as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Antioxidants; Benzothiazoles; Benzylamines; Biphen | 2021 |
Design, synthesis and biological evaluation of harmine derivatives as potent GSK-3β/DYRK1A dual inhibitors for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Cell Line; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; Dyr | 2021 |
[Blood pressure increases risk for dementia and stroke. Antihypertensive drugs for mental degeneration?].
Topics: Alzheimer Disease; Antihypertensive Agents; Atenolol; Cerebral Infarction; Clinical Trials as Topic; | 2004 |